// App-Quantinova.ai

3627 : Identification Of Markers Of Thrombotic Risk and Response To Cytoreductive Intervention In Philadelphia-Chromosome Negative Myeloproliferative Neoplams

Researchers

Presenter

  • Gabriela Soriano Hobbs

Principal Investigators

  • Minal Patel

  • Young Rock Chung

  • Omar Abdel-Wahab

  • Gerald A. Soff

  • Raajit K. Rampal

Medical Centers

  • Lymphoma Service, Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, NY

  • Clinical Genetics Service, Memorial Sloan-Kettering Cancer Center, New York, NY

  • Department of Medicine, Leukemia Service, Memorial Sloan Kettering Cancer Center, New York, NY

  • Memorial Sloan Kettering Cancer Center, Port Washington, NY

  • Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY

Locations

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Myeloid neoplasms

  • Essential thrombocythemia

  • Polycythemia vera

  • Myelofibrosis

  • Venous thrombosis

Biomarkers

  • Platelet Factor 4

Drug/Treatment

  • Pomalidomide

  • CC-4047

  • Hydroxyurea

  • Hydroxycarbamide

  • Ruxolitinib phosphate

  • Methadone hydrochloride

  • Aspirin

  • Albyl-E

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Interim

Copyright © 2026. QuantiNova All rights reserved